Department of Surgery, University of Colorado Denver, CO, USA.
Crit Care Med. 2012 Sep;40(9):2647-53. doi: 10.1097/CCM.0b013e3182592006.
We hypothesized that aerosolized inhaled hypertonic saline given at the onset of resuscitation will decrease acute lung injury following hemorrhagic shock, by inhibiting the release of epithelial derived proinflammatory mediators.
Animal study.
Animal-care facility procedure room in a medical center.
Adult male Sprague-Dawley rats.
Rats underwent hemorrhagic shock followed by 2 hrs of resuscitation and 1 hr of observation. In the study group, nebulized hypertonic saline was delivered at the end of the shock period and after 1 hr and 2 hrs of resuscitation.
Shock provoked acute lung injury, which was attenuated with inhaled hypertonic saline (1.56 ± 0.2 mg protein/mL vs. 0.95 ± 0.3 mg protein/mL bronchoalveolar lavage fluid, shock vs. shock + hypertonic saline, p < .01). Nebulized hypertonic saline reduced inflammation (cytokine-induced neutrophil chemoattractant-1 accumulation in bronchoalveolar lavage fluid 5999 ± 1267 pg/mL vs. 3342 ± 859 pg/mL, shock vs. shock + hypertonic saline, p = .006). Additionally, nebulized hypertonic saline inhibited matrix -metalloproteinase-13 accumulation in the bronchoalveolar lavage fluid (1513 ± 337 pg/mL bronchoalveolar lavage fluid vs. 230 ± 19 pg/mL, shock vs. shock + hypertonic saline, p = .009) and pretreatment with a matrix metalloproteinase-13 inhibitor was sufficient to attenuate postshock acute lung injury (1.42 ± 0.09 mg/mL vs. 0.77 ± 0.23 mg/mL bronchoalveolar lavage protein, shock vs. shock + matrix metalloproteinase-13 inhibitor CL-82198, p = .002).
Inhaled hypertonic saline attenuates postshock acute lung injury by exerting an anti-inflammatory effect on the pulmonary epithelium, suggesting a new clinical strategy to treat acute lung injury/acute respiratory distress syndrome.
我们假设,在复苏开始时给予雾化吸入高渗盐水,通过抑制上皮衍生的促炎介质的释放,可减少失血性休克后的急性肺损伤。
动物研究。
医疗中心的动物护理设施程序室。
成年雄性 Sprague-Dawley 大鼠。
大鼠经历失血性休克,随后进行 2 小时复苏和 1 小时观察。在研究组中,在休克期结束时以及复苏后 1 小时和 2 小时给予雾化高渗盐水。
休克引起急性肺损伤,雾化高渗盐水可减轻这种损伤(支气管肺泡灌洗液中的蛋白 1.56 ± 0.2 mg/mL 与 0.95 ± 0.3 mg/mL,休克与休克+高渗盐水,p <.01)。雾化高渗盐水可减轻炎症(支气管肺泡灌洗液中的细胞因子诱导的中性粒细胞趋化因子-1 积聚 5999 ± 1267 pg/mL 与 3342 ± 859 pg/mL,休克与休克+高渗盐水,p =.006)。此外,雾化高渗盐水可抑制基质金属蛋白酶-13 在支气管肺泡灌洗液中的积聚(支气管肺泡灌洗液中的 1513 ± 337 pg/mL 与 230 ± 19 pg/mL,休克与休克+高渗盐水,p =.009),并且基质金属蛋白酶-13 抑制剂预处理足以减轻休克后急性肺损伤(支气管肺泡灌洗液中的蛋白 1.42 ± 0.09 mg/mL 与 0.77 ± 0.23 mg/mL,休克与休克+基质金属蛋白酶-13 抑制剂 CL-82198,p =.002)。
雾化高渗盐水通过对肺上皮发挥抗炎作用减轻休克后急性肺损伤,提示一种治疗急性肺损伤/急性呼吸窘迫综合征的新临床策略。